Stephens Investment Management Group LLC lifted its stake in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 1.7% during the third quarter, HoldingsChannel.com reports. The firm owned 780,419 shares of the company’s stock after purchasing an additional 13,055 shares during the quarter. Twist Bioscience makes up about 1.6% of Stephens Investment Management Group LLC’s portfolio, making the stock its 6th largest holding. Stephens Investment Management Group LLC’s holdings in Twist Bioscience were worth $150,808,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Twist Bioscience in the 2nd quarter worth approximately $600,191,000. William Blair Investment Management LLC purchased a new position in Twist Bioscience during the second quarter valued at $223,722,000. Bank of America Corp DE purchased a new position in Twist Bioscience during the second quarter valued at $94,922,000. Bank of New York Mellon Corp bought a new stake in Twist Bioscience in the second quarter worth $19,722,000. Finally, Russell Investments Group Ltd. boosted its holdings in Twist Bioscience by 190.8% in the third quarter. Russell Investments Group Ltd. now owns 283,910 shares of the company’s stock worth $54,863,000 after acquiring an additional 186,294 shares in the last quarter.
Wall Street Analyst Weigh In
TWST has been the topic of a number of recent research reports. Robert W. Baird cut their target price on Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, November 13th. Piper Sandler upped their price target on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. Jefferies Financial Group set a $125.00 price target on shares of Twist Bioscience in a research note on Thursday, November 12th. Royal Bank Of Canada set a $137.00 price objective on shares of Twist Bioscience in a research report on Friday, November 13th. Finally, Guggenheim raised their price objective on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $133.92.
View Our Latest Stock Report on TWST
Insider Activity at Twist Bioscience
In related news, insider Dennis Cho sold 9,514 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,797,004.32. Following the sale, the insider owned 63,789 shares in the company, valued at approximately $12,048,466.32. This trade represents a 12.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of Twist Bioscience stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the completion of the sale, the senior vice president directly owned 106,632 shares of the company’s stock, valued at approximately $20,140,652.16. This trade represents a 8.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 495,279 shares of company stock valued at $80,489,387 over the last ninety days. Company insiders own 3.08% of the company’s stock.
Twist Bioscience Trading Up 3.9%
Twist Bioscience stock opened at $116.35 on Thursday. Twist Bioscience Corporation has a one year low of $25.23 and a one year high of $219.71. The business’s fifty day moving average is $149.33 and its 200 day moving average is $94.12. The stock has a market capitalization of $7.30 billion, a PE ratio of -55.67 and a beta of 2.25. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. The business had revenue of $126.64 million for the quarter, compared to analysts’ expectations of $123.55 million. Twist Bioscience had a negative net margin of 28.34% and a negative return on equity of 27.53%. The business’s quarterly revenue was up 26.7% compared to the same quarter last year. On average, sell-side analysts predict that Twist Bioscience Corporation will post -1.42 EPS for the current year.
Twist Bioscience Profile
Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.
Further Reading
- Five stocks we like better than Twist Bioscience
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
